Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2018

01-09-2018 | Original Article

Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California

Authors: Mike Wei, Jason Ford, Qihan Li, Donghak Jeong, Allison J. Kwong, Mindie H. Nguyen, Matthew S. Chang

Published in: Digestive Diseases and Sciences | Issue 9/2018

Login to get access

Abstract

Background

Patients with cirrhosis are at high readmission risk. Using a large statewide database, we evaluated the effect of hospital cirrhosis-related patient volume on 30-day readmissions in patients with cirrhosis.

Methods

We conducted a retrospective study of the Healthcare Cost and Utilization Project State Inpatient Database for adult patients with cirrhosis, as defined by International Classification of Diseases, Ninth Revision (ICD-9) codes, hospitalized in California between 2009 and 2011. Multivariable logistic regression analysis was performed to evaluate the effect of hospital volume on 30-day readmissions.

Results

A total of 69,612 patients with cirrhosis were identified in 405 hospitals; 24,062 patients were discharged from the top 10% of hospitals (N = 41) by cirrhosis volume, and 45,550 patients in the bottom 90% (N = 364). Compared with higher-volume centers, lower-volume hospitals cared for patients with similar average Quan–Charlson–Deyo (QCD) comorbidity scores (6.54 vs. 6.68), similar proportion of hepatitis B and fatty liver disease, lower proportion of hepatitis C (34.8 vs. 41.5%) but greater proportion of alcoholic liver disease (53.1 vs. 47.4%). Multivariable logistic regression analysis demonstrated admission to a lower-volume hospital did not predict 30-day readmission (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.92–1.01) after adjusting for sociodemographics, QCD score, cirrhosis severity, and hospital characteristics. Instead, liver transplant center status significantly decreased the risk of readmission (OR 0.87, 95% CI 0.80–0.94). Ascites, hepatic encephalopathy, hepatocellular carcinoma, higher QCD, and presence of alcoholic liver disease and hepatitis C were also independent predictors.

Conclusions

Readmissions within 30 days were common among patients with cirrhosis hospitalized in California. While hospital cirrhosis volume did not predict 30-day readmissions, liver transplant center status was protective of readmissions. Medically complicated patients with cirrhosis at hospitals without liver transplant centers may benefit from additional support to prevent readmission.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:709–717.CrossRefPubMed Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:709–717.CrossRefPubMed
2.
go back to reference Volk ML, Tocco RS, Bazick J, et al. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107:247–252.CrossRefPubMed Volk ML, Tocco RS, Bazick J, et al. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107:247–252.CrossRefPubMed
3.
go back to reference Kim WR, Brown RS, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242.CrossRefPubMed Kim WR, Brown RS, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242.CrossRefPubMed
4.
go back to reference Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol. 2011;7:661–671. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol. 2011;7:661–671.
5.
go back to reference Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016;14:e1182. Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016;14:e1182.
7.
go back to reference Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428.CrossRefPubMed Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428.CrossRefPubMed
8.
go back to reference Miller ME. Report to the Congress: Reforming the Delivery System. Washington, DC: Medicare Payment Advisory Commission; 2008. Miller ME. Report to the Congress: Reforming the Delivery System. Washington, DC: Medicare Payment Advisory Commission; 2008.
10.
go back to reference Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011;155:520–528.CrossRefPubMed Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011;155:520–528.CrossRefPubMed
11.
go back to reference Tapper EB, Volk M. Strategies to reduce 30-day readmissions in patients with cirrhosis. Curr Gastroenterol Rep. 2017;19:1.CrossRefPubMed Tapper EB, Volk M. Strategies to reduce 30-day readmissions in patients with cirrhosis. Curr Gastroenterol Rep. 2017;19:1.CrossRefPubMed
12.
go back to reference Kanwal F, Asch SM, Kramer JR, et al. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016;64:569–581.CrossRefPubMed Kanwal F, Asch SM, Kramer JR, et al. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016;64:569–581.CrossRefPubMed
13.
go back to reference Mellinger JL, Richardson CR, Mathur AK, et al. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13:577–584.CrossRefPubMed Mellinger JL, Richardson CR, Mathur AK, et al. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13:577–584.CrossRefPubMed
14.
go back to reference Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137.CrossRefPubMed Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137.CrossRefPubMed
15.
16.
go back to reference Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med. 2011;154:94–102.CrossRefPubMedPubMedCentral Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med. 2011;154:94–102.CrossRefPubMedPubMedCentral
17.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed
18.
go back to reference Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011;9:254–259.CrossRefPubMed Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011;9:254–259.CrossRefPubMed
19.
go back to reference Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64:200–208.CrossRefPubMedPubMedCentral Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64:200–208.CrossRefPubMedPubMedCentral
20.
go back to reference Heron M. Deaths: leading causes for 2013. Natl Vital Stat Rep. 2016;65:1–95.PubMed Heron M. Deaths: leading causes for 2013. Natl Vital Stat Rep. 2016;65:1–95.PubMed
Metadata
Title
Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California
Authors
Mike Wei
Jason Ford
Qihan Li
Donghak Jeong
Allison J. Kwong
Mindie H. Nguyen
Matthew S. Chang
Publication date
01-09-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4964-0

Other articles of this Issue 9/2018

Digestive Diseases and Sciences 9/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine